You’re pushing microbiome therapies closer to real clinical and commercial impact. But along the way, you may be recognizing how challenging it can be to clearly demonstrate mechanism, build investor confidence, and secure pharma partnerships in a competitive and evolving space.
The 11th Microbiome Movement USA Summit is built around these realities. It’s where you can turn shared challenges into clear strategies for progress.
At this year’s summit, you will:
- Explore how LBPs and FMTs are being applied across multiple indications to unlock clinically meaningful, commercially viable opportunities
- Learn from companies advancing towards pharma partnerships to understand what strong data and MoA must be demonstrated
- Understand first-time investor expectations to position your program for broader funding and long-term growth
Unmissable Event Highlights
Validate Novel Assays to Strengthen Regulatory & Investor Confidence
Adopt next-generation analytical strategies to demonstrate identity, potency, and viability, so you can generate robust, regulator-ready analytical data that helps avoid clinical delays.
Hear from:
- Jason Goldsmith, Senior Director, Medical, Translational & Data Science, Nestle Health Science
- Philip Burnham, Chief Scientific Officer, Kanvas Biosciences
Engage Pharma Earlier with Credible Mechanistic & Clinical Evidence
Learn how to package MoA, biomarker, and early clinical data effectively, to overcome skepticism and secure long-term pharma partnerships early.
Hear from:
- Benjamin Hadida, Co-Founder & Chief Executive Officer, Exeliom Biosciences
- Henry Haiser, Operating Partner, Corundum Systems Biology
- Ken Blount, Senior Vice President, Head of Microbiome Clinical & Product Development, Ferring Pharmaceuticals
Explore Commercial Pathways Beyond Traditional Therapeutic Routes
Join a cross-industry discussion on LBP vs direct-to-consumer strategies, to assess alternative routes to generate revenue and validate your therapy earlier.
Hear From:
- Bernat Olle, Chief Executive Officer, Vedanta Biosciences
- Momo Vuyisich, Chief Scientific Officer & Head of Clinical Research, Viome
- Giana Jarrah, Founder & Chief Executive Officer, Meraki Co
- Todd Krueger, Chief Executive Officer, AOBiome
Position Your Program to Meet Mainstream VC Investment Criteria
Understand how biotech investors assess microbiome platforms, so you can align your data and narrative to attract funding in a highly selective market.
Hear from:
- Vanessa Ridaura, Senior Program Officer, Microbiome Products, The Gates Foundation
- Sathya Janardhanan, Venture Partner, Ecphora Capital
- Henry Haiser, Operating Partner, Corundum Systems Biology
- Denise Kelly, Investment Advisor, Seventure Partners
Explore the 2026 Event Guide
- Join >80% C-level, VPs, and Directors to identify and connect with key opinion leaders in the microbiome space
- See the LBP and FMT coverage to pinpoint sessions most relevant to your program
- See active investors and strategic partners attending to refine your funding and partnering strategy
- Pharma insights from Ferring and ex-Takeda leaders to understand how to secure pharma support
- Learn from Vedanta, MRM Health, and AOBiome to overcome clinical setbacks and scale microbiome-based therapies
Attending Companies Include
Explore the Agenda
Dive into real-world strategies tackling microbiome credibility, clinical efficacy, and regulatory hurdles so you can move your program forward with confidence.
Partner With Us
Position your solution at the centre of microbiome dealmaking as biotechs actively seek partners to validate, fund, and scale their programs.
Join Biopharma Experts
Connect with microbiome leaders across R&D, CMC, and BD to exchange insights, overcome shared challenges, and build partnerships that accelerate clinical and commercial success.